Belatacept and Long-Term Outcomes in Kidney Transplantation | Zendy

Flavio Vincenti | Zendy; Lionel Rostaing | Zendy; J.M. Boria Grinyo | Zendy; Kim Rice | Zendy; Steven Steinberg | Zendy; Luis Gaite | Zendy; MarieChristine Moal | Zendy; Guillermo Mondragón-Ramírez | Zendy; Jatin Kothari | Zendy; Martin S. Polinsky | Zendy; HerwigUlf MeierKriesche | Zendy; Stéphane Munier | Zendy; Christian P. Larsen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Belatacept and Long-Term Outcomes in Kidney Transplantation

Author(s) -

Flavio Vincenti,

Lionel Rostaing,

J.M. Boria Grinyo,

Kim Rice,

Steven Steinberg,

Luis Gaite,

MarieChristine Moal,

Guillermo Mondragón-Ramírez,

Jatin Kothari,

Martin S. Polinsky,

HerwigUlf MeierKriesche,

Stéphane Munier,

Christian P. Larsen

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1506027

Subject(s) - belatacept , immunosuppression , medicine , kidney transplantation , kidney transplant , term (time) , kidney , transplantation , urology , renal function , physics , quantum mechanics

In previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as compared with cyclosporine-based immunosuppression, was associated with similar patient and graft survival and significantly improved renal function in kidney-transplant recipients. Here we present the final results from this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research